Transcriptional regulation of the immune checkpoints PD-1 and CTLA-4.
作者信息
Guo Jing, Xue Zhonghui, Wang Lie
机构信息
Institute of Immunology and Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, 310006, China.
Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA, 94305, USA.
出版信息
Cell Mol Immunol. 2022 Jul;19(7):861-862. doi: 10.1038/s41423-022-00877-y. Epub 2022 May 20.
Abstract
摘要
相似文献
1
Transcriptional regulation of the immune checkpoints PD-1 and CTLA-4.
Cell Mol Immunol. 2022 Jul;19(7):861-862. doi: 10.1038/s41423-022-00877-y. Epub 2022 May 20.
2
Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer.
J Exp Clin Cancer Res. 2021 Jun 4;40(1):184. doi: 10.1186/s13046-021-01987-7.
3
DNA methylation and repressive H3K9 and H3K27 trimethylation in the promoter regions of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, and PD-L1 genes in human primary breast cancer.
Clin Epigenetics. 2018 Jun 15;10:78. doi: 10.1186/s13148-018-0512-1. eCollection 2018.
4
Immunomodulatory role for MicroRNAs: Regulation of PD-1/PD-L1 and CTLA-4 immune checkpoints expression.
Gene. 2020 Sep 5;754:144888. doi: 10.1016/j.gene.2020.144888. Epub 2020 Jun 13.
5
DNA methylation and repressive histones in the promoters of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, PD-L1, and galectin-9 genes in human colorectal cancer.
Clin Epigenetics. 2018 Aug 6;10(1):104. doi: 10.1186/s13148-018-0539-3.
6
New B7 Family Checkpoints in Human Cancers.
Mol Cancer Ther. 2017 Jul;16(7):1203-1211. doi: 10.1158/1535-7163.MCT-16-0761.
7
Expression of immune checkpoint regulators, cytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed death-ligand 1 (PD-L1), in female breast carcinomas.
PLoS One. 2018 Apr 19;13(4):e0195958. doi: 10.1371/journal.pone.0195958. eCollection 2018.
8
Association of PD-1, PD-L1, and CTLA-4 Gene Expression and Clinicopathologic Characteristics in Patients With Non-Small-Cell Lung Cancer.
Clin Lung Cancer. 2017 Mar;18(2):e109-e116. doi: 10.1016/j.cllc.2016.09.010. Epub 2016 Oct 17.
9
Correlation between messenger RNA expression and protein expression of immune checkpoint-associated molecules in bladder urothelial carcinoma: A retrospective study.
Urol Oncol. 2017 May;35(5):257-263. doi: 10.1016/j.urolonc.2017.01.014. Epub 2017 Mar 11.
10
CTLA-4 Synergizes With PD1/PD-L1 in the Inhibitory Tumor Microenvironment of Intrahepatic Cholangiocarcinoma.
Front Immunol. 2021 Aug 30;12:705378. doi: 10.3389/fimmu.2021.705378. eCollection 2021.
引用本文的文献
1
Current trends in sensitizing immune checkpoint inhibitors for cancer treatment.
Mol Cancer. 2024 Dec 26;23(1):279. doi: 10.1186/s12943-024-02179-5.
2
Pan-cancer multi-omics analysis of PTBP1 reveals it as an inflammatory, progressive and prognostic marker in glioma.
Sci Rep. 2024 Jun 25;14(1):14584. doi: 10.1038/s41598-024-64979-5.
3
PlexinB1 Inactivation Reprograms Immune Cells in the Tumor Microenvironment, Inhibiting Breast Cancer Growth and Metastatic Dissemination.
Cancer Immunol Res. 2024 Sep 3;12(9):1286-1301. doi: 10.1158/2326-6066.CIR-23-0289.
4
Constructing a T-Cell Receptor-Related Gene Signature for Prognostic Stratification and Therapeutic Guidance in Head and Neck Squamous Cell Carcinoma.
Cancers (Basel). 2023 Nov 21;15(23):5495. doi: 10.3390/cancers15235495.
Zotero 插件